GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » OWC Pharmaceutical Research Corp (OTCPK:OWCP) » Definitions » Forward Rate of Return (Yacktman) %

OWCP (OWC Pharmaceutical Research) Forward Rate of Return (Yacktman) % : 0.00% (As of Sep. 2019)


View and export this data going back to 2008. Start your Free Trial

What is OWC Pharmaceutical Research Forward Rate of Return (Yacktman) %?

Yacktman defines forward rate of return as the normalized free cash flow yield plus real growth plus inflation. OWC Pharmaceutical Research's forward rate of return for was 0.00%.

The historical rank and industry rank for OWC Pharmaceutical Research's Forward Rate of Return (Yacktman) % or its related term are showing as below:

OWCP's Forward Rate of Return (Yacktman) % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 5.98
* Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.

Unlike the Earnings Yield %, the Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.


OWC Pharmaceutical Research Forward Rate of Return (Yacktman) % Historical Data

The historical data trend for OWC Pharmaceutical Research's Forward Rate of Return (Yacktman) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OWC Pharmaceutical Research Forward Rate of Return (Yacktman) % Chart

OWC Pharmaceutical Research Annual Data
Trend Dec08 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18
Forward Rate of Return (Yacktman) %
Get a 7-Day Free Trial Premium Member Only - - - - -

OWC Pharmaceutical Research Quarterly Data
Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19
Forward Rate of Return (Yacktman) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of OWC Pharmaceutical Research's Forward Rate of Return (Yacktman) %

For the Drug Manufacturers - Specialty & Generic subindustry, OWC Pharmaceutical Research's Forward Rate of Return (Yacktman) %, along with its competitors' market caps and Forward Rate of Return (Yacktman) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


OWC Pharmaceutical Research's Forward Rate of Return (Yacktman) % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, OWC Pharmaceutical Research's Forward Rate of Return (Yacktman) % distribution charts can be found below:

* The bar in red indicates where OWC Pharmaceutical Research's Forward Rate of Return (Yacktman) % falls into.


;
;

OWC Pharmaceutical Research Forward Rate of Return (Yacktman) % Calculation

Forward Rate of Return is a concept that Don Yacktman uses in his investment approach. Yacktman explained the forward rate of return concept in detail in his interview with GuruFocus. Yacktman defines forward rate of return as the normalized free cash flow yield plus real growth plus inflation. He said in the interview (March 2012, when the S&P 500 was at about 1400):

If the business is stable, this calculation is fairly straightforward. For instance, on the S&P 500 we would normalize earnings. We would then calculate what percentage of those earnings are not reinvested in the underlying businesses and are therefore free. Historically, for the S&P 500, this has been just under 50% of earnings. Currently, we expect the S&P to earn about 70 on a normalized basis, a number which is far below reported earnings due to our adjusting for record high profit margins. $70 X ½ / 1400 gives you a normalized free cash flow yield of approximately 2.5%.

The historical real growth rate of the S&P 500 (companies) is about 1.5%. Assuming an inflation rate of 2.5%, the forward rate of return on an investment in the S&P 500 is about 6.5% today (2.5% free cash flow yield plus 1.5% real growth plus 2.5% inflation).

OWC Pharmaceutical Research's Forward Rate of Return of Sep. 2019 is

Forward Rate of Return=Normalized Free Cash Flow/Price+5-Year EBITDA Growth Rate
=0/0.01+0
=0.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


OWC Pharmaceutical Research  (OTCPK:OWCP) Forward Rate of Return (Yacktman) % Explanation

Unlike the Earnings Yield, the Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.

For the growth part of the Forward Rate of Return calculation, GuruFocus uses the 5-year average growth rate of EBITDA per share as the growth rate, and the growth rate is always capped at 20%. For the Free Cash Flow we use per share data averaged over five years. The reason we use five years is to make it comparable to the growth rate.


Be Aware

In the Forward Rate of Return calculation, the growth rate is added directly to today's free cash flow yield. Therefore the calculation is reliable only if the company can grow at the same rate in the future as it did in the past. Investors should pay close attention to this when researching growth stocks. A more accurate measurement for return is Return on Capital.


OWC Pharmaceutical Research Forward Rate of Return (Yacktman) % Related Terms

Thank you for viewing the detailed overview of OWC Pharmaceutical Research's Forward Rate of Return (Yacktman) % provided by GuruFocus.com. Please click on the following links to see related term pages.


OWC Pharmaceutical Research Business Description

Traded in Other Exchanges
N/A
Address
2 Ben Gurion Street, Ramat Gan, ISR, 5257334
OWC Pharmaceutical Research Corp is a medical cannabis research and development company. The firm through its subsidiary researches and develops cannabis-based products and treatments specifically designed for multiple myeloma, psoriasis, fibromyalgia, post-traumatic stress disorder (PTSD), migraine, sexual function and skin disorders. It also provides consulting services to governmental and private entities to assist them with developing and implementing tailor-made medical cannabis program.
Executives
Asher Zwebner director, officer: CHIEF FINANCIAL OFFICER CDOOR CORPORATION, 20 A REHOV SHAREI TORAH BAYIT VEGAN, JERUSALEM L3 96387

OWC Pharmaceutical Research Headlines